We previously developed more than 27 different cell-penetrating VDAC1-based peptides as a decoy to compete with VDAC1 for binding to its associated proteins that were tested for apoptosis induction in chronic lymphocytic leukemia (CLL)-derived lymphocytes [16] and in other cell types [26] and evaluated in glioblastoma, breast, and lung cancer mouse models [18,26]. Here, VDAC1 is linked to lung carcinoma.